ALTIMMUNE, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
ALTIMMUNE, INC. (ALT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $181.96 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-14.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2017-03-14
- ALTIMMUNE, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2016 was $181.96K, a 82.67% decline from fiscal 2015.
- ALTIMMUNE, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2015 was $1.05M, a 175.75% increase from fiscal 2014.
- ALTIMMUNE, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2014 was $380.69K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2016-12-31 | $181.96K 10-K · filed 2017-03-14 |
| 2015-12-31 | $1.05M 10-K · filed 2017-03-14 |
| 2014-12-31 | $380.69K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |